Insulin Glulisine
- Generic Name
- Insulin Glulisine
- Brand Names
- Apidra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 207748-29-6
- Unique Ingredient Identifier
- 7XIY785AZD
- Background
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insul...
- Indication
用于治疗成人糖尿病。
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Hyperglycemia during critical illness
- Associated Therapies
- -
Effect of LIXIsenatide on the Renal System
- Conditions
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 40
- Registration Number
- NCT02276196
- Locations
- 🇳🇱
VU Universtiy Medical Center, Amsterdam, Netherlands
Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 14
- Registration Number
- NCT02048189
- Locations
- 🇫🇷
CHU de Dijon, Dijon, France
🇫🇷CHU de Besancon, Besancon, France
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 456
- Registration Number
- NCT01848990
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Madison, Wisconsin, United States
Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 64
- Registration Number
- NCT01678235
- Locations
- 🇵🇱
Department of Pediatrics, Medical University of Warsaw, Poland, Warsaw, Poland
Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Sansum Diabetes Research Institute
- Target Recruit Count
- 17
- Registration Number
- NCT01662921
- Locations
- 🇺🇸
William Sansum Diabetes Center, Santa Barbara, California, United States
Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 107
- Registration Number
- NCT01621776
- Locations
- 🇺🇸
Camp Winona, DeLeon Springs, Florida, United States
Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2011-12-29
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT01500850
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Rheinland-Pfalz, Germany
Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- HealthPartners Institute
- Target Recruit Count
- 12
- Registration Number
- NCT01436045
- Locations
- 🇺🇸
HealthPartners Specialty Center - Center for Dementia & Alzheimer's Care, St. Paul, Minnesota, United States
Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2012-03-05
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 12
- Registration Number
- NCT01417897
- Locations
- 🇩🇪
ife GmbH, Clinic, Mainz, Rhineland-Palatinate, Germany
Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
- Conditions
- Interventions
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2013-07-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 161
- Registration Number
- NCT01212913
- Locations
- 🇰🇷
Administrative Office, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.